8.30-8.45
Opening remarks day 1: Philipp Steven

8.45-10.30
Session 1: Pathogenesis and risk factors of ocular GVHD, Yoko Ogawa and Victor Perez

1.     Development of ocular GVHD – Victor Perez, Miami
2.     Animal models in ocular GVHD – TBA
3.     Fibrosis in ocular GHVD – Yoko Ogawa, Tokyo
4.     Risk factors of ocular GVHD – Martina Maaß, Cologne

10.30-10.45
Coffee break

10.45-12.15
Session 2: Diagnosis and grading of ocular GVHD, Margarita Calonge and Carrie L. Kitko

1.     Grading and diagnosing GVHD in other organs –Carrie L. Kitko, Nashville
2.     Current grading schemes for ocular GVHD – Tina Dietrich-Ntoukas, Berlin
3.     ProposalforearlydiagnostisofocularGVHD–TBA
4.    Biomarkers–MargaritaCalonge,Valladolid

12.15-14.00
Lunch Break

14.00-15.30 
Session3:Noveltargetsand(preventive) therapies,SandeepJainandDanielWolff

1.     Stratification of chronic GVHD – Daniel Wolff, Regensburg
2.     Preventive therapies fo ocular GVHD – Leonie Menghesha, Cologne
3.     Pooled Human Globulins – Sandeep Jain, Chicago
4.     Regenerative topical therapies – Volkan Tahmaz, Cologne

15.30-15.45
Coffee break

15.45-17.15
Session 4: Translational science: other organs and the eye, Chairs: Michael E. Stern and TBD

1.     Manifestation of systemic immunity in the eye – Michael E. Stern, Irvine/Cologne
2.     Severe ocular surface disease and similarities to oGVHD – TBA
3.     Angiogenesis in acute and chronic GVHD – Katarina Riesner, Berlin
4.     Skin GVHD – Mirjana Ziemer

17.15-18.00
Roundtable discussion,
Moderators:
Christof Scheid and Philipp Steven

1.     How can we better translate basic research into the clinic?
2.     How could we attract more ophthalmologists to GVHD care?

SATURDAY, MARCH 9TH I DAY 2

8.30               
Opening remarks day 2: Christof Scheid

8.45-10.15
Session 5: Patient-centered care, Udo Holtick

1.     My Story: The ocular GVHD patient
2.     Digital solutions in peri- and post-transplant care – TBA
3.     Rehabilitation of patients with severe ocular surface disease – Kathleen Kunert, Masserberg
4.     Optimizing peri- and post-transplant care – Udo Holtick, Cologne

10.15-10.30
Coffee break

10.30-12.00    
Session 6: Novel concepts in allogeneic transplantation and cellular therapy, Daniel Wolff and Christof Scheid

1.     Immunotherapy and allogeneic transplantation in ALL – TBA
2.     Refractory lymphoma: CART or transplantation or both – TBA
3.     Beyond transplantation: immunotherapy in myeloma – Christof Scheid
4.     New approaches to treat GvHD – TBA
5.     Cellular therapy for viral complications – TBA

12.00-12.30
Wrap up: What’s new, what have we learned.

12.30             
Farewell comments, Philipp Steven and Christof Scheid

Bitte wenden Sie sich für weitere Informationen direkt an den Organisator.